WKYMVM-NH2 TFA |
| Catalog No.GC63384 |
WKYMVM-NH2 TFA es un potente receptor de péptido N-formilo (FPR1) y agonista de FPRL1/2, también activa varias funciones efectoras de leucocitos como la quimiotaxis, la movilizaciÓn del receptor del complemento-3 y la activaciÓn de la NADPH oxidasa .
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1435781-74-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
WKYMVM-NH2 TFA is a potent N-formyl peptide receptor (FPR1) and FPRL1/2 agonist, also activates several leukocyte effector functions such as chemotaxis, mobilization of complement receptor-3, and activation of the NADPH oxidase[1][2][3].
WKYMVM-NH2 TFA (10-1000 nM; 24 hours) induces Caco-2 cells proliferation[3].
WKYMVM-NH2 TFA (8 mg/kg; six times; for 5 days) ameliorates DSS-induced ulcerative colitis[3].WKYMVM-NH2 TFA affects cytokine (IL-17, IFN-γ, IL-6, IL-1β and TNF-α) profiles in the DSS colitis model[3].
[1]. Christophe T, et al. The synthetic peptide Trp-Lys-Tyr-Met-Val-Met-NH2 specifically activates neutrophils through FPRL1/lipoxin A4 receptors and is an agonist for the orphan monocyte-expressed chemoattractant receptor FPRL2. J Biol Chem. 2001 Jun 15;276(24):21585-93.
[2]. Christophe T, et al. Phagocyte activation by Trp-Lys-Tyr-Met-Val-Met, acting through FPRL1/LXA4R, is not affected by lipoxin A4. Scand J Immunol. 2002 Nov;56(5):470-6.
[3]. Sang Doo Kim, et al. The immune-stimulating peptide WKYMVm has therapeutic effects against ulcerative colitis. Exp Mol Med. 2013 Sep; 45(9): e40.
Average Rating: 5 (Based on Reviews and 5 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *